close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CuraSen Therapeutics, Inc.

News headline image
Phase 2a Clinical Data Show CuraSen Therapeutics’ CuraAX (CST-3056) Met Primary Endpoint Demonstrating Statistically Significant Improvement in Standing Systolic Blood Pressure in Patients with Neurogenic Orthostatic Hypotension (nOH)
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics to Present Late-Breaking, Phase 2a Exploratory Data with CuraAX (CST-3056) in Patients with Neurogenic Orthostatic Hypotension (nOH) at the 37th International Symposium on the Autonomic Nervous System
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease
From CuraSen Therapeutics, Inc.
Via Business Wire
News headline image
CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease
From CuraSen Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.